NASH is a severe form of non-alcoholic fatty liver disease without any FDA-approved treatments. However, many companies are working towards an effective treatment, with several in late-stage trials. Five leading contenders are Galectin Therapeutics with its product belapectin; Galmed Pharmaceuticals with Aramchol; Inventiva Pharma with lanifibranor; Madrigal Pharmaceuticals with resmetirom; and 89bio with pegozafermin. The NASH treatment market is expected to reach $48.3 billion by 2035.
![](https://healsecurity.com/wp-content/uploads/2024/09/cdc-issues-warning-over-recalled-eggs-sold-in-three-states.jpg)
CDC issues warning over recalled eggs sold in three states
The Centers for Disease Control and Prevention (CDC) has issued a warning against recalled eggs linked to 24 hospitalizations due to salmonella infection. The eggs,